Pazopanib
Pazopanib is a multi-kinase inhibitor that inhibits the VEGF receptors VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively, in a cell-free enzyme assay).{37765} It also inhibits PDGFR?, PDGFR?, and c-Kit (IC50s = 71, 84, and 74 nM, respectively, in a cell-free enzyme assay) as well as additional receptor tyrosine kinases. Pazopanib inhibits upregulation of the surface adhesion proteins ICAM-1 and VCAM-1 induced by VEGF in multiple myeloma cells cocultured with human umbilical vein endothelial cells (HUVECs) and decreases multiple myeloma cell adhesion to HUVECs.{29172} It also inhibits proliferation of multiple myeloma cells cocultured with HUVECs. Pazopanib (30 and 100 mg/kg) reduces tumor growth, induces apoptosis, decreases angiogenesis, and increases survival in a multiple myeloma mouse xenograft model. Formulations containing pazopanib have been used in the treatment of cancer.
Do you have any questions about this product?
Order your product by email
Productname
Pazopanib
12097-50
By filling out this form, you are placing an order by e-mail. You will receive an order confirmation within one working day. The order cannot be modified after receipt of the order confirmation.
Request a sample
Productname
Pazopanib
12097-50
By filling out this form, you request a sample. You will receive an order confirmation within one working day. The order cannot be modified after receipt of the order confirmation.
Are you looking for specific products, alternatives or documentation?
